GIST Support UK News

Please see the latest news, research and findings below...

Scottish Sarcoma Network – 2013

Patients who are interested, are welcome to attend any of the Sarcoma education days, which you can see on the Scottish Sarcoma Network website. www.ssn.scot.nhs.uk/ Any patients that are interested in these days, or would be interested in extra support, find out about available services or need help with any concerns are encouraged to get […]

Continue reading

Pub Quiz in aid of Gist Support UK – 2013

The Pub Quiz on Oct 17 in Tooting was an absolutely fantastic evening and success. First and foremost, the biggest mention must go to Barbara’s sister Jan for putting together the event pretty much single-handedly by all accounts – even persuading her son to fly in from Moscow – that is serious fundraising for you! […]

Continue reading

GSUK helps to fund GIST research – 2012

On 20th August we were delighted to present our medical consultant, Professor Ian Judson, with a cheque for £20,000 to help support a new research project. Professor Judson plans to collect data on all the patients who are being or have been treated at the Royal Marsden Hospital, in order to study the correlation between […]

Continue reading

SMC approves adjuvant use of Imatinib – 2012

Imatinib (Glivec) has been accepted for restricted use within Scotland for certain high risk GIST adult patients. The SMC accepted that adjuvant imatinib for three years compared to one year significantly improved survival. However, this treatment has yet to be approved by NICE for England & Wales. Click here for full details from SMC.

Continue reading

The PleurX system – 2012

This new approach to the treatment of ascites has just been approved by NICE. It comprises a catheter and collection vessel which the patient can continue to wear at home, so that he does not need to make repeated visits to hospital everytime fluid needs to be drained. Click here here to read the full text of […]

Continue reading

European Commission approves extending adjuvant therapy with Glivec to three years for certain GIST patients – 2012

Novartis announced on 27th February that the European Commission (EC) has approved an update to the Glivec® (imatinib)* label to include 36 months of treatment after surgery for adults with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the inclusion criteria of the pivotal study. This extended treatment regimen has been shown to improve recurrence-free […]

Continue reading

MASITINIB Trial – February 2012

On 1ST February AB Science published a press release announcing encouraging results from a phase2 trial of their drug masitinib. The trial compared masitinib vs sunitinib for the second-line treatment of patients with locally advanced or metastatic imatinib-resistant GIST. Members of SPAEN and clinical experts felt at the time that AB Science’s claims were premature. […]

Continue reading